U.S. subsidiary

Note on the entity name: the database records the defendant only as "U.S. subsidiary." The sole tracked case, Celgene Corporation v. Sun Pharmaceutical Industries et al. (D.N.J.), names Sun Pharmaceutical Industries, Inc. among the defendants alongside Sun Pharma Global FZE, Sun Pharma Global Inc., and Sun Pharmaceutical Industries Limited. This profile therefore describes Sun Pharmaceutical Industries, Inc., the U.S. arm of Sun Pharmaceutical Industries Limited ("Sun Pharma"); the parent-level facts below are verified, but entity-level data for the U.S. corporation specifically is limited.

Ownership, HQ, size. Sun Pharmaceutical Industries, Inc. is a wholly owned subsidiary of Sun Pharmaceutical Industries Limited, an Indian multinational d/b/a Sun Pharma, founded in 1983 by Dilip Shanghvi and listed in India in 1994. The parent trades on NSE (SUNPHARMA) and BSE (524715) with a market capitalization in the range of ₹4.4–4.5 lakh crore (roughly US$47–50 billion as of late 2025), FY2025 revenue of about ₹52,578 crore (about US$6.6 billion), and roughly 43,000 employees worldwide; the Shanghvi family holds about 54%. The U.S. subsidiary is headquartered at 2 Independence Way, Princeton, New Jersey, with later operations in Cranbury and New Brunswick. New Jersey state filings and Sun Pharma announcements put more than 600 employees in New Jersey and describe a new 100,000-square-foot Princeton U.S. headquarters (750 College Road East) announced in 2025 with roughly 450 corporate jobs.

Operations. Sun Pharma develops, manufactures, and markets generic and branded prescription drugs, specialty medicines, consumer healthcare products, and active pharmaceutical ingredients, with U.S. operations spanning distribution, manufacturing, and R&D. It is commonly described as the world's fourth-largest specialty generic pharmaceutical company and the largest Indian pharma company in the U.S.

Litigation posture. An operating company, not a non-practicing entity: zero plaintiff cases and one defendant case in the tracked data — consistent with a generic manufacturer being sued by a brand owner. The single tracked D.N.J. matter is Hatch-Waxman ANDA litigation; no plaintiff-friendly Texas venue appears.

Notable case. Celgene Corp. v. Sun Pharmaceutical Industries, Inc., et al., No. 2:18-cv-11630 (D.N.J., filed July 13, 2018), concerned Sun's proposed generic lenalidomide (Revlimid) and asserted U.S. Patents 7,465,800; 7,855,217; and 7,968,569. A related 2019 suit (No. 19-cv-10099) asserted non-Orange-Book patents. The parties settled in June 2021 with a licensing and entry schedule.